VolitionRx Limited has announced the successful validation and verification of the chemiluminescent immunoassay version of its Nu.Q Vet Cancer Test with Fujifilm Vet Systems Co. Ltd in Japan. This development enables full automation in central laboratories through the IDS i10 automated analyzer platform, marking a significant advancement in veterinary diagnostic capabilities.
The transition from manual plates to automated processing is expected to support faster turnaround times and higher throughput as demand for veterinary cancer testing grows. More than 1,700 veterinary hospitals in Japan are already registered to use the test, indicating substantial existing adoption that could be enhanced by automation. Japan's approximately seven million pet dogs represent a significant market for improved veterinary diagnostics.
The automated platform aligns with the same system used for Volition's human Nu.Q Cancer, Nu.Q NETs and Nu.Q Discover products, underscoring cross-platform synergy between human and veterinary applications. This technological consistency may facilitate knowledge transfer and operational efficiencies across different diagnostic applications.
Volition is a multi-national company focused on advancing the science of epigenetics and is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.
The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For further information about the company's broader initiatives, visit https://volition.com/.
The automation validation represents a strategic development in veterinary medicine, potentially improving access to cancer screening for pets in Japan. Faster processing capabilities could lead to earlier detection and intervention, which may improve treatment outcomes and quality of life for companion animals. The scalability offered by automation may also make cancer testing more accessible to a broader range of veterinary practices beyond specialized centers.
This development occurs within the context of growing recognition of companion animal health and the human-animal bond, where pet owners increasingly seek advanced medical care for their animals. The alignment with human diagnostic platforms suggests potential for integrated health monitoring approaches that could benefit both veterinary and human medicine through shared technological infrastructure and research insights.
